Durability of virologic response, risk of de novo hepatocellular carcinoma, liver function and stiffness 2 years after treatment with ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in the AMBER, real-world experience study. [electronic resource]
Producer: 20190906Description: 1298-1305 p. digitalISSN:- 1365-2893
- 2-Naphthylamine
- Adult
- Aged
- Anilides -- pharmacology
- Antiviral Agents -- pharmacology
- Carbamates -- pharmacology
- Carcinoma, Hepatocellular -- epidemiology
- Cyclopropanes
- Drug Therapy, Combination
- Female
- Follow-Up Studies
- Genotype
- Hepacivirus -- drug effects
- Hepatitis C, Chronic -- drug therapy
- Humans
- Lactams, Macrocyclic
- Liver -- drug effects
- Liver Cirrhosis -- drug therapy
- Liver Neoplasms -- epidemiology
- Macrocyclic Compounds -- pharmacology
- Male
- Middle Aged
- Poland -- epidemiology
- Proline -- analogs & derivatives
- Ribavirin -- pharmacology
- Ritonavir -- pharmacology
- Sulfonamides -- pharmacology
- Treatment Outcome
- Uracil -- analogs & derivatives
- Valine
- Viral Load -- drug effects
No physical items for this record
Publication Type: Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.